10:21 AM EDT, 07/11/2025 (MT Newswires) -- Immix Biopharma ( IMMX ) said Friday the safety profile for its investigational CAR-T cell therapy NXC-201 includes an "absence of neurotoxicity of any grade in low-volume disease."

The company said this safety profile supports "potential future indication expansion."

Immix Biopharma ( IMMX ) also said it remains on track to submit a biologics license application for NXC-201 to treat relapsed/refractory AL Amyloidosis, a disease caused by abnormal plasma cells in the bone marrow.

Price: 2.69, Change: -0.02, Percent Change: -0.70